Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Drugs

Retrieve available abstracts of 10 articles:
HTML format
Text format



Single Articles


    November 2017
  1. SCOTT LJ
    Correction to: Opicapone: A Review in Parkinson's Disease.
    Drugs. 2017 Nov 21. doi: 10.1007/s40265-017-0847.
    PubMed     Text format     Abstract available


    September 2016
  2. SCOTT LJ
    Erratum to: Opicapone: A Review in Parkinson's Disease.
    Drugs. 2016.
    PubMed     Text format    


    August 2016
  3. CHANG A, Fox SH
    Erratum to: Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
    Drugs. 2016.
    PubMed     Text format    


  4. SCOTT LJ
    Opicapone: A Review in Parkinson's Disease.
    Drugs. 2016.
    PubMed     Text format     Abstract available


    July 2016
  5. MARKHAM A
    Pimavanserin: First Global Approval.
    Drugs. 2016;76:1053-7.
    PubMed     Text format     Abstract available


    June 2016
  6. CHANG A, Fox SH
    Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
    Drugs. 2016.
    PubMed     Text format     Abstract available


    May 2016
  7. VIJAYAKUMAR D, Jankovic J
    Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
    Drugs. 2016;76:759-77.
    PubMed     Text format     Abstract available


  8. VIJAYAKUMAR D, Jankovic J
    Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
    Drugs. 2016;76:779-87.
    PubMed     Text format     Abstract available


    November 2015
  9. PARK A, Stacy M
    Disease-Modifying Drugs in Parkinson's Disease.
    Drugs. 2015.
    PubMed     Text format     Abstract available


    April 2015
  10. DEEKS ED
    Safinamide: first global approval.
    Drugs. 2015;75:705-11.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: